Table of Contents
- What Is Treatment-Resistant Depression?
- Signs of Treatment-Resistant Depression
- How Is Treatment-Resistant Depression Diagnosed?
- Step 1: Psychiatric Evaluation and Patient History
- Step 2: Reviewing Antidepressant Trials
- Step 3: Ruling Out Comorbid Conditions and Other Factors
- Step 4: Staging the Level of Resistance
- Step 5: Using Validated Rating Scales
- Step 6: Distinguishing TRD From Difficult-to-Treat Depression
- Step 7: When to Seek a Specialist Evaluation
- Treatment Options for Resistant Depression
- Medication Management for Depression
- Psychosocial and Lifestyle Interventions
- Patient Advocacy and Self-Advocacy
- Long-Term Prognosis and Recovery Outlook
- Frequently Asked Questions
Last Updated: September 15, 2026
What Is Treatment-Resistant Depression?
Treatment-resistant depression is major depressive disorder that does not improve adequately after at least two different antidepressants at appropriate doses for sufficient durations (Questions and Answers about the NIMH Sequenced Treatment Alternatives to Relieve…). It is not a separate diagnosis in the standard manual clinicians use, but a clinical label applied when first-line medications fail.
The distinction matters: a single medication that doesn’t work is common, but treatment-resistant depression requires a pattern of multiple adequate trials, each given a fair chance, with little to no clinical remission.
The National Institute of Mental Health’s overview of depression notes that depression is one of the most treatable mental health conditions, yet a significant portion of patients do not respond to the first treatment they try. Understanding why that happens, and what to do next, is the entire point of this guide.
Signs of Treatment-Resistant Depression
The signs of treatment-resistant depression look at first like any depressive episode: persistent low mood, loss of interest, sleep disruption, fatigue, difficulty concentrating, and hopelessness that doesn’t lift.
What sets treatment-resistant depression apart is the timeline and pattern of response: symptoms persist despite treatment, or improve briefly and return. Patients often describe a “honeymoon period” of a few weeks where a new medication seems to help, followed by a slow slide back.
Common indicators include:
- Symptoms that persist after two or more adequate antidepressant trials
- Partial improvement that never reaches clinical remission
- Repeated relapses after initial therapeutic response
- Worsening symptoms despite treatment adherence
- Side effects that force discontinuation before an adequate duration is reached
The single most important sign is not the severity of symptoms, but the pattern: adequate treatment, inadequate response, repeated across multiple attempts.
How Is Treatment-Resistant Depression Diagnosed?
Diagnosis of treatment-resistant depression is a clinical process, not a single test, no blood test, brain scan, or genetic marker confirms it. A psychiatric evaluation builds a longitudinal picture of your symptom history, medication trials, and response patterns.
The goal is to answer three questions: Was each prior trial adequate? Are comorbid conditions complicating the picture? Is something else mimicking or worsening depression?
Step 1: Psychiatric Evaluation and Patient History
A thorough psychiatric evaluation starts with your full history: when symptoms began, how they’ve changed, what treatments you’ve tried, and how you responded. The clinician will ask about family history of mood disorders, prior psychiatric hospitalizations, and trauma.
This step also screens for substance use, medical conditions that mimic depression (like thyroid disorders or anemia), and medication interactions. Skipping this depth is how patients end up on their fifth medication without anyone asking why the first four failed.
Step 2: Reviewing Antidepressant Trials
Each prior antidepressant trial is evaluated for adequate dose, adequate duration, and adherence. A three-week trial at a subtherapeutic dose doesn’t count the same as eight weeks at a full dose.
Response is graded: full remission means symptoms largely resolve; partial response means meaningful improvement short of remission; no response means no measurable difference. Treatment-resistant depression typically requires at least two failed trials with adequate dose and duration.
Step 3: Ruling Out Comorbid Conditions and Other Factors
Depression rarely travels alone. Anxiety disorders, PTSD, ADHD, and substance use frequently co-occur and blunt the effectiveness of standard antidepressants. Comorbid conditions must be identified and addressed, or treatment keeps hitting a ceiling.
This step also considers psychosocial factors: chronic stress, unresolved grief, ongoing abuse, financial strain, or isolation. These aren’t “just” life problems, they shape neurobiology and treatment response measurably.
Step 4: Staging the Level of Resistance
Once the history is assembled, clinicians often assign a stage to describe how resistant the depression has been. Two frameworks appear most often.
The Thase and Rush staging model assigns a Roman numeral based on how many distinct antidepressant classes have failed: Stage I, one adequate trial of a single class; Stage II, two classes from different families; Stage III, a tricyclic; Stage IV, a monoamine oxidase inhibitor; Stage V, electroconvulsive therapy. Higher stages generally predict lower response rates to the next standard medication.
The Maudsley Staging Method is more granular, scoring three dimensions, episode duration, symptom severity, and the number and adequacy of prior trials, to classify resistance as mild, moderate, or severe. Because it captures episode length and symptom burden alongside trial count, it often tracks real-world outcomes more closely than a simple class count.
Neither system is a formal diagnosis in the standard manual clinicians use. They are descriptive tools that help a prescriber decide how aggressive the next step should be.
Step 5: Using Validated Rating Scales
Because patient recall is unreliable, clinicians anchor the diagnosis in standardized scales, most commonly:
- PHQ-9, a nine-item self-report that maps directly to the major depressive episode criteria; scores of 5, 10, 15, and 20 mark mild, moderate, moderately severe, and severe ranges.
- MADRS, a ten-item clinician-rated scale widely used in research and in tracking treatment response over time.
- QIDS-SR16, a sixteen-item self-report designed to measure symptom severity and change, useful for comparing trials.
- HAM-D, the Hamilton Rating Scale for Depression, a legacy clinician-rated instrument still used in many clinical trials.
Response is generally a 50 percent or greater reduction from baseline; remission is a score below a defined threshold (under 5 on the PHQ-9, under 10 on the MADRS) (pubmed.ncbi.nlm.nih.gov). Documenting these numbers separates a defensible TRD diagnosis from a vague impression that “nothing worked.”
A TRD diagnosis rests on documented adequacy, dose, duration, adherence, and measured response, not on the patient’s or clinician’s memory of how a medication felt.
Step 6: Distinguishing TRD From Difficult-to-Treat Depression
The two terms are often used interchangeably but are not the same. Treatment-resistant depression is narrower: at least two adequate antidepressant trials without remission. Difficult-to-treat depression is broader, it includes cases where treatment was never truly adequate, side effects forced early discontinuation, a comorbid condition went unaddressed, or psychosocial barriers prevented adherence.
The distinction matters because the next step differs. Genuinely resistant depression may need an interventional treatment such as transcranial magnetic stimulation or a ketamine-derived therapy; difficult-to-treat depression may simply need a properly dosed trial, a treated comorbid condition, or a removed barrier. Mislabeling the second group as the first leads to unnecessary escalation.
Step 7: When to Seek a Specialist Evaluation
A general psychiatrist can manage most first- and second-line trials. Referral to a specialist or mood disorders program is reasonable when:
- Two or more adequate trials have failed
- Symptoms are severe, or there is any suicidal ideation
- Comorbid psychiatric or medical conditions complicate the picture
- The patient has not responded to an interventional treatment
- The diagnosis itself is uncertain
A specialist evaluation is not a sign that prior care failed. It is the appropriate next step once the standard sequence has been exhausted.
Treatment Options for Resistant Depression
Treatment options for resistant depression go beyond switching to another standard antidepressant. Once two adequate trials have failed, guidelines point toward augmentation, combination therapy, and newer interventions with distinct mechanisms of action.
The right path depends on your symptom profile, medical history, and prior responses. What follows is a plain-language map of the main categories and who tends to be a candidate.
Switching Versus Augmenting
When a first medication fails, there are two broad moves. Switching means stopping the current antidepressant and starting a different one, usually from another class, an SSRI to an SNRI, a tricyclic, or an atypical such as bupropion or mirtazapine. Augmenting means keeping it and adding a second agent with a different mechanism.
Switching is often preferred when the first medication caused intolerable side effects or no response at all; augmentation when it produced a partial response, enough to suggest the mechanism is partly right, but not enough for remission.
Adjunctive Pharmacotherapy
Pharmacogenetic Testing
Interventional Treatments
Psychotherapy Combined With Medication
How the Choice Gets Made
Ask your prescriber to document each trial formally: medication, dose, duration, and response. This record becomes the backbone of any treatment-resistant depression diagnosis and saves months of backtracking later.
Interventional treatments such as ECT, esketamine, and VNS are not first-line options. They are considered after standard medication strategies have failed, and each carries its own monitoring requirements and side-effect profile. Discuss the risks and benefits with a qualified clinician before deciding.
Medication Management for Depression
Ask your prescriber to document each trial formally: medication, dose, duration, and response. This record becomes the backbone of any treatment-resistant depression diagnosis and saves months of backtracking later.
Psychosocial and Lifestyle Interventions
Patient Advocacy and Self-Advocacy
Long-Term Prognosis and Recovery Outlook
Frequently Asked Questions
What qualifies as treatment-resistant depression?
Treatment-resistant depression (TRD) is typically diagnosed when a person has tried at least two different antidepressants at adequate doses for an adequate duration (usually 6-8 weeks each) without achieving clinical remission. Some definitions also consider the number of failed trials and the severity of symptoms. A psychiatric evaluation can determine if your depression meets the criteria for TRD.
How can you tell if your current depression treatment is failing?
Signs that your treatment may not be working include persistent sadness, loss of interest in activities, changes in sleep or appetite, difficulty concentrating, and thoughts of self-harm. If you’ve been on an antidepressant for several weeks and see little improvement, talk to your doctor. They may adjust the dose, switch medications, or add adjunctive therapy.
What are the clinical steps to diagnose treatment-resistant depression?
Diagnosis involves a thorough psychiatric evaluation, including a detailed patient history of depressive episodes and prior treatments. Your doctor will review antidepressant trials to confirm adequate dose and duration, and may use rating scales to assess symptom severity. They will also rule out other conditions that can mimic depression, such as thyroid disorders or substance use.
Does treatment-resistant depression ever go away?
With the right treatment plan, many people with treatment-resistant depression experience significant improvement or remission. Options include switching to a different class of antidepressants, adding adjunctive medications, trying neuromodulation therapies like TMS or ketamine, or participating in clinical trials. Recovery is possible, but it often requires a personalized approach and ongoing medication management.
What role does medication management play in treating resistant depression?
Medication management for depression involves regular monitoring of your response to medications, adjusting doses, and managing side effects. For resistant depression, your psychiatrist may combine multiple medications, use pharmacogenetic testing to guide choices, or prescribe newer options like esketamine. Consistent follow-up and open communication with your provider are key to finding an effective regimen.
